Name
GS2-02 - Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link